Opioidergic inhibition of luteinising hormone and prolactin release changes during pregnancy in pony mares.
In equine species, luteinising hormone (LH) and prolactin (PRL) release are reduced throughout pregnancy but increase at foaling. The present experiments were designed to study a possible opioidergic regulation of LH and PRL release in pregnant Shetland mares (n=6). At various stages of pregnancy (days 26.4+/-0.6, 75.4+/-5.4, 171.8+/-2.4, 226.2+/-4.8, 282.7+/-3.4 and 319.8+/-2.1), mares were injected with the opioid antagonist naloxone (0.5 mg/kg body weight) and saline. The two treatments were always separated by 2 days, and mares served as their own controls. Two hours after being given naloxone and saline, mares were given the gonadotrophin-releasing hormone (GnRH) analogue buserelin (5 microg per animal). The naloxone experiment was repeated at 2 days after foaling. Blood for the determination of LH and PRL was withdrawn at 15 min intervals for 240 min, and naloxone or saline was injected after 60 min. Naloxone induced significant (P<0.05) LH release on days 172, 226 and 283 of pregnancy but not on days 26, 76 and 320 and 2 days after foaling. Buserelin caused a significant (P<0.05) increase in plasma LH concentrations on days 172, 226, 282 and 320 of pregnancy. The experiments indicate that endogenous opioids are involved in the inhibition of LH release during the second half of pregnancy in equine species. The deactivation of opioid effects on LH release might be a prerequisite for the onset of ovarian activity postpartum. Plasma PRL concentrations increased significantly (P<0.05) after naloxone administration on days 226, 282 and 320 of pregnancy. The naloxone-induced PRL release was most pronounced towards term, indicating an increase in the naloxone-releasable pool and/or the absence of other PRL-release inhibitory mechanisms.
Aurich
C
C
Centre for Artificial Insemination and Embryo Transfer, University of Veterinary Sciences, Veterinärplatz 1, 1210 Vienna, Austria. christine.aurich@vu-wien.ac.at
Aurich
J E
JE
Parvizi
N
N
D000818:Animals; D002064:Buserelin / Q000494:pharmacology; D005260:Female; D005300:Fertility Agents, Female / Q000494:pharmacology; D006736:Horses / Q000097:blood / Q000502:physiology*; D007986:Luteinizing Hormone / Q000097:blood / Q000378:metabolism*; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D018847:Opioid Peptides / Q000037:antagonists & inhibitors / Q000502:physiology*; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000097:blood / Q000502:physiology*; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000097:blood / Q000378:metabolism*
D005300:Fertility Agents, Female; D009292:Narcotic Antagonists; D018847:Opioid Peptides; D009270:Naloxone; D011374:Progesterone; D011388:Prolactin; D007986:Luteinizing Hormone; D002064:Buserelin